- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06927921
Assessement of the Knoweldge ,Attitudes,Practices of Diabetic Kidney Disease Among Diabetic Patients
Assessemnt of the Knoweldge ,Attitudes and Practices of Diabetic Kidney Disease Among Diabetic Patients
Study Overview
Status
Conditions
Detailed Description
Diabetic kidney disease is defined as patients with diabetes mellitus who have persistent proteinuria for at least three consecutive measurements per year, or a decrease in GFR (<90 ml/min/1.73m²) .Diabetic kidney disease is a severe microvascular complication frequently associated with both type 1 and type 2 diabetes mellitus, is a leading cause of renal failure. The condition can also lead to accelerated cardiovascular disease and macrovascular complications.
In Egypt, DM is a dilemma and a fast-expanding concern. According to the International Diabetes Federation (IDF), the prevalence of DM among Egyptian adults is 15.2%, which may be an underestimation.Public awareness, knowledge, and preventive practices are crucial in mitigating the onset and progression of diabetic nephropathy. Gaining insights into the general population's awareness, knowledge, attitudes, and practices (A-KAP) pertaining to this condition is crucial for the development of effective educational campaigns and preventative strategies.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Sara Abdelaziz Hassan Mahmoud, Resident doctor
- Phone Number: 01013619689
- Email: S01013619689@gmail.com
Study Contact Backup
- Name: Radwa Awad Abdelhafiz Ibrahim, Doctor
- Phone Number: 01003797448
- Email: radwaawad@aun.edu.eg
Study Locations
-
-
-
Assuit, Egypt
- Assuit university
-
Contact:
- Sara Abdelaziz Hassan Mahmoud, resident doctor
- Phone Number: 01013619689
- Email: s010136196892@gmail.com
-
Assuit university, Egypt
- Assuit university
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- • Diabetic patients (either type 1or 2 DM ) with age above 18yrs old.
Exclusion Criteria:
• CKD patients due to cause other than diabetes.
- Patients who refuse participation in the study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
evaluation of the knowledge, attitude and practice of chronic kidney disease among the diabetic patients through a questionnaire
Time Frame: Baseline
|
CKD screening index, which is divided into three different scales. The knowledge scale consists of 24 items regarding general knowledge of CKD, including its definition, risk factors, signs, symptoms, and complications. The attitudes scale, composed of 15 items, was used to assess the attitudes of diabetic patients toward CKD signs and symptoms and the ability to seek appropriate social and medical help related to their concerns. The practice score consists of 12 items that evaluate the health practices of each patient to prevent CKD. The validity and reliability of this screening index were examined and guaranteed and used in its arabic edition in another study . The correct answer was given one point, zero points for an incorrect answer, a Therefore, more correct answers meant greater knowledge of DM. |
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Salah Abdelazeem Ahmed Seleem, Prof, Assiut University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- assessment of diabetic kidney
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.